A Big Study Found that Semaglutide Users Saw Increased Health Spending. Should We Be Surprised?

There’s a long Arc today on a detailed IRA-related argument that deserves a (more) detailed response. At least, it’s long by my standards (650 words), and I feel it’s fair

We have our final two: it’ll be the CMS list of “selected drugs” under the IRA against the approval of Leqembi in the finals of Cost Curve Fight Club. You

There may be no drug-pricing myth more pernicious than the idea that the NIH does all the drug research, and companies just sweep in at the eleventh hour, ram medicines